B2M and B-cell non-Hodgkin lymphoma: Here we show that, as for the 5G10 clone, we detected a specific labeling of the CLBL-1 cell line at day 29 compared with the pre-immune serum (day 0) attesting, as expected, that CD22 is expressed by canine B-cell lymphoma and that the immunization with soluble CD22c-β2m is efficient at generating the production of antibodies able to bind the CD22c on its native form.